Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast for systemic sclerosis
2025-523884-39-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 45
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) comparing Nerandomilast (BI 1015550) with Placebo (2 arms). Primary endpoint: Time to the first occurrence of disease progression or all-cause death. Planned start Sep 2026; status: authorised.
02
Drugs
nerandomilast
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2025-523884-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523884-39-00.